Delivery Order SPE2DB24D2205-SPE2DB24FDTFX
Award Date 4/29/24
Potential Completion Date 4/30/24
Potential Value $2K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $4,194.81 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 1,000 units of the drug Tamsulosin HCL 0.4 mg capsules. The contract has an ultimate completion date of March 31, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the procurement of 1,000 units of the drug Tamsulosin Hydrochloride 0.4 mg capsules. The contract has a firm fixed price of $1,791.90 and a period of performance through March 26, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical to...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Tamsulosin HCl 0.4 mg capsules. The order has a ceiling value of $2,039.99 and an ultimate completion date of February 21, 2024. The contract is a firm fixed-price instrument without any set-aside designation, indicating open competition. AmerisourceBergen holds a large Indefinite Delivery Contract (IDC)...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of 4,567,721,093 units of Tamsulosin HCL 0.4 mg capsules, with a ceiling value of $2,585.21. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,566,544,849 units of Tamsulosin HCL 0.4 mg capsules. The contract has a ceiling value of $5,142.60 and a period of performance through November 26, 2024. This appears to be a Firm Fixed Price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. The delivery order has a firm fixed price of $2,520.38 and a period of performance through March 31, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of 1,000 units of the prescription drug Tamsulosin HCL 0.4 mg capsules. The contract has a fixed ceiling value of $5,357.29 and a performance period ending on March 25, 2025. The contract is a Delivery Order and is priced on a Firm Fixed Price basis. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,865.14, is for the delivery of 1,000 units of the medication Tamsulosin HCL 0.4 mg capsules. The contract has an ultimate completion date of November 21, 2023 and is a firm fixed-price delivery order. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,346.80, is for the delivery of 1,000 units of the drug Tamsulosin HCL 0.4 mg capsules. The contract is a Delivery Order placed under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which has a ceiling value of $999,999,999 and runs through November 2026. The contract is a...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,020.20, is for the delivery of 1,000 units of the drug Tamsulosin HCL 0.4 MG Capsule. The contract has a completion date of February 20, 2025 and is a firm fixed-price contract. This contract award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB24FDTFXDelivery Order
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Tamsulosin HCl 0.4 mg capsules. The contract has a ceiling value of $2,018.95 and a period of performance through April 30, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.
Generated 5/16/25, 11:50 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 4/29/24 |